Evidence map›Paper›PMID 33927343›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021

Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.

Elisavet Kaltsouni, Patrick M Fisher, Manon Dubol, Steinar Hustad, Rupert Lanzenberger, Vibe G Frokjaer, Johan Wikström, Erika Comasco, Inger Sundström-Poromaa

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Aging · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Elisavet KaltsouniDepartment of Neuroscience, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Patrick M FisherNeurobiology Research Unit, Department of Neurology, Copenhagen University Hospital Rigshospitalet-Blegdamsvej, Copenhagen, Denmark.
Manon DubolDepartment of Neuroscience, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Steinar HustadDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Rupert LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-4641-9539
Vibe G FrokjaerNeurobiology Research Unit, Department of Neurology, Copenhagen University Hospital Rigshospitalet-Blegdamsvej, Copenhagen, Denmark.
Johan WikströmDepartment of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.
Erika Comasco *Department of Neuroscience, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. erika.comasco@neuro.uu.se.ORCID http://orcid.org/0000-0002-2174-2068
Inger Sundström-Poromaa *Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Uppsala University · SECopenhagen University Hospital · DKMedical University of Vienna · ATMental Health Services · DKUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premenstrual dysphoric disorder (PMDD) is a psychiatric condition characterized by late luteal phase affective, cognitive, and physical impairment. The disorder causes significant suffering in about 5% of women in their reproductive age. Altered sensitivity of cognitive-affective brain circuits to progesterone and its downstream metabolite allopregnanolone is suggested to underlie PMDD symptomatology. Core mood symptoms include irritability and anger, with aggression being the behavioral outcome of these symptoms. The present study sought to investigate the neural correlates of reactive aggression during the premenstrual phase in women with PMDD, randomized to a selective progesterone receptor modulator (SPRM) or placebo. Self-reports on the Daily Record of Severity of Problems were used to assess PMDD symptoms and gonadal hormone levels were measured by liquid chromatography tandem mass spectrometry. Functional magnetic resonance imaging was performed in 30 women with PMDD, while performing the point subtraction aggression paradigm. Overall, a high SPRM treatment response rate was attained (93%), in comparison with placebo (53.3%). Women with PMDD randomized to SPRM treatment had enhanced brain reactivity in the dorsal anterior cingulate cortex and dorsomedial prefrontal cortex during the aggressive response condition. The fronto-cingulate reactivity during aggressive responses depended on treatment, with a negative relationship between brain reactivity and task-related aggressiveness found in the placebo but not the SPRM group. The findings contribute to define the role of progesterone in PMDD symptomatology, suggesting a beneficial effect of progesterone receptor antagonism, and consequent anovulation, on top-down emotion regulation, i.e., greater fronto-cingulate activity in response to provocation stimuli.

Indexed as

Premenstrual Dysphoric DisorderReceptors, ProgesteroneAggressionBrainFemaleHumansLuteal PhasePregnanoloneProgesteronePregnanoloneProgesteroneReceptors, Progesterone

Identifiers

PMID33927343
PMCPMC8209206
OpenAlexW3158800702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.